Gotowe bibliografie tematyczne / Non-small cell lung cancer

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „Non-small cell lung cancer”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 25 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Non-small cell lung cancer”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Non-small cell lung cancer"

1

Cheng, Wenhan, M. D, MS c, et al. "Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer." International Journal of Medical Reviews and Case Reports 4, Reports in Clinical Medicine and (2020): 1. http://dx.doi.org/10.5455/ijmrcr.atezolizumab-non-small-cell-lung-cancer.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Skenduli, Ilir, and Perlat Kapisyzi. "Surgery for Non Small Cell Lung Cancer - A Systematic Review." International Journal of Science and Research (IJSR) 11, no. 5 (2022): 1551–56. http://dx.doi.org/10.21275/sr22518021202.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Hellriegel, H. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Klaus-Peter, K. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-6-12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Kammaev, K. A. "Non-small cell lung carcinoma. Clinical case." Filin’s Clinical endoscopy 66, no. 3 (2024): 62–65. http://dx.doi.org/10.31146/2415-7813-endo-66-3-62-65.

Pełny tekst źródła
Streszczenie:
In 2020, 2.2 million new cases of lung cancer were reported. The main form of lung cancer is non-small cell carcinoma (85%). Non-small cell lung cancer has 3 subtypes: adenocarcinoma, large cell and squamous cell carcinoma. Squamous cell lung cancer occurs in 20-40% of all lung cancers. Squamous cell lung cancer is associated with an unfavorable outcome. 5-year survival rate not exceeding 18%.
Style APA, Harvard, Vancouver, ISO itp.
6

_, _. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 6, no. 3 (2008): 228. http://dx.doi.org/10.6004/jnccn.2008.0021.

Pełny tekst źródła
Streszczenie:
Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States
Style APA, Harvard, Vancouver, ISO itp.
7

Skřičková, Jana, Bohdan Kadlec, and Ondřej Venclíček. "Non-small cell lung cancer." Vnitřní lékařství 63, no. 11 (2017): 861–74. http://dx.doi.org/10.36290/vnl.2017.159.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Ettinger, David S., Wallace Akerley, Gerold Bepler, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 8, no. 7 (2010): 740–801. http://dx.doi.org/10.6004/jnccn.2010.0056.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Ettinger, David S., Wallace Akerley, Hossein Borghaei, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 10, no. 10 (2012): 1236–71. http://dx.doi.org/10.6004/jnccn.2012.0130.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Fromer, Margot J. "Non-Small-Cell Lung Cancer." Oncology Times 30, no. 4 (2008): 21–25. http://dx.doi.org/10.1097/01.cot.0000313049.69678.f6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Non-small cell lung cancer"

1

Kapeleris, Joanna C. "Circulating tumour cells in non-small cell lung cancer." Thesis, Queensland University of Technology, 2022. https://eprints.qut.edu.au/228607/1/Joanna_Kapeleris_Thesis.pdf.

Pełny tekst źródła
Streszczenie:
Circulating tumour cells (CTCs) have the potential to transform the management of patients with non-small cell lung cancer (NSCLC). The applications of CTCs can identify clinically actionable targets to predict treatment response and to better understand metastasis. CTCs isolated using microfluidics can be used as prognostic indicators of NSCLC as well as characterizing for markers of immunotherapy (PD-L1), molecular targets (ALK, EGFR). Short term cultures were successfully expanded in 9/70 NSCLC patients and cultured for up to 3 months. Optimization of this novel CTC culture model provides o
Style APA, Harvard, Vancouver, ISO itp.
2

Sikkink, Stephen K. "Genetic pathology of non-small cell lung cancer." Thesis, University of Liverpool, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.250405.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Wong, Wing-sze, and 黃詠詩. "Fusion genes in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43781378.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Swinson, Daniel. "Hypoxic markers in non-small cell lung cancer." Thesis, University of Leicester, 2004. http://hdl.handle.net/2381/29476.

Pełny tekst źródła
Streszczenie:
Hypoxia is an important factor in the pathogenesis of solid tumours. Hypoxia inducible factors (HIF)-1alpha and HIF-2alpha are transcription factors that in part mediate the cellular response to hypoxia. These transcription factors are involved in the regulation of angiogenesis, anaerobic metabolism, pH homeostasis, erythropoiesis and cell death.;Immunohistochemical (IHC) assays were optimised for HIF-1alpha and one of its transcriptional targets, Carbonic Anhydrase (CA) IX. Attempts to optimise an IHC assay for HIF-2alpha failed to produce reproducible staining. A scoring system was also devi
Style APA, Harvard, Vancouver, ISO itp.
5

Wong, Wing-sze. "Fusion genes in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B43781378.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Brena, Romulo Martin. "Aberrant DNA methylation in human non-small cell lung cancer." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1172083621.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Brattström, Daniel. "Angiogenesis related markers in non-small cell lung cancer /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl.[distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3558.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Xinarianos, George. "Genetic alterations in non-small cell lung carcinomas." Thesis, University of Liverpool, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.343688.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Brattström, Daniel. "Angiogenesis Related Markers In Non-Small Cell Lung Cancer." Doctoral thesis, Uppsala University, Oncology, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3558.

Pełny tekst źródła
Streszczenie:
<p>This thesis investigated the predictive and the prognostic powers of angiogenesis related markers in both operable and inoperable non-small cell lung cancer (NSCLC) patients.</p><p>In the first and second study, we investigated the serological fractions of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 2 cohorts of patients with either operable or inoperable NSCLC. </p><p>Regarding operable NSCLC, we demonstrated significant correlations between VEGF and tumour volume and overall survival. Regarding bFGF, significant correlations with recurrent diseas
Style APA, Harvard, Vancouver, ISO itp.
10

Lam, Chi-leung David. "Gene expression profiling in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38585777.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Non-small cell lung cancer"

1

T, Carr David, and International Cancer Research Data Bank., eds. Non-small cell lung cancer. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Ramaswamy, Govindan, ed. Locally advanced non-small-cell lung cancer. CMP United Business Media, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

S, Seeber, ed. Small cell lung cancer. Springer-Verlag, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Seeber, Siegfried, ed. Small Cell Lung Cancer. Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-82372-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

1935-, Skarin Arthur T., and Alexander Eben, eds. Multimodality treatment of lung cancer. M. Dekker, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Ettinger, David S. The role of chemotherapy in non-small cell lung cancer. Bristol Laboratories Oncology Products, Bristol-Myers Oncology Division, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Benjamin, Movsas, Langer Corey J, and Goldberg Melvyn, eds. Controversies in lung cancer: A multidisciplinary approach. M. Dekker, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Jerome, Seidenfeld, Blue Cross and Blue Shield Association. Technology Evaluation Center., and United States. Agency for Healthcare Research and Quality., eds. Management of small cell lung cancer. Agency for Healthcare Research and Quality, Public Health Service, U.S. Dept. of Health and Human Services, 2006.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Postmus, Pieter Edsge. New approaches in small cell lung cancer. [s.n.], 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Carr, David T. Selected abstracts on small cell lung cancer. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Non-small cell lung cancer"

1

Munden, Reginald F., and Jeremy J. Erasmus. "Thoracic Imaging Techniques for Non-Small Cell and Small Cell Lung Cancer." In Lung Cancer. Springer New York, 2003. http://dx.doi.org/10.1007/0-387-22652-4_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Rosell, Rafael, and Delvys Rodriguez-Abreu. "Non-Small-Cell Lung Cancer." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_4119-3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Rosell, Rafael, and Delvys Rodriguez-Abreu. "Non-Small-Cell Lung Cancer." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_4119.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Rosell, Rafael, and Delvys Rodriguez-Abreu. "Non-Small Cell Lung Cancer." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4119.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Hansen, Heine H. "Non-Small Cell Lung Cancer: Staging and Surgery." In Lung Cancer. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76031-0_18.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Hansen, Heine H. "Non-Small Cell Lung Cancer: Radiotherapy and Chemotherapy." In Lung Cancer. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76031-0_19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Cox, James D., and David J. Stewart. "Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer." In Lung Cancer. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Wahl, Michael, Matthew A. Gubens, and Sue S. Yom. "Non-small Cell Lung Cancer." In Handbook of Evidence-Based Radiation Oncology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-62642-0_15.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Nguyen, Quynh-Nhu, Ritsuko Komaki, Daniel R. Gomez, and Zhongxing Liao. "Non-small Cell Lung Cancer." In Intensity-Modulated Radiation Therapy. Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-55486-8_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Jabbari, Siavash, Eric K. Hansen, and Daphne A. Haas-Kogan. "Non-small Cell Lung Cancer." In Handbook of Evidence-Based Radiation Oncology. Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-92988-0_15.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Non-small cell lung cancer"

1

Hano, Harun, Beatriz Suarez, Charles H. Lawrie, and Andreas Seifert. "Raman Spectroscopy Detects Biochemical Signatures in Non-Small Cell Lung Cancer." In 2024 International Conference on Optical MEMS and Nanophotonics (OMN). IEEE, 2024. http://dx.doi.org/10.1109/omn61224.2024.10685276.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Azarya, Irgi, Tri Arief Sardjono, Nada Fitrieyatul Hikmah, and Norma Hermawan. "Non-Small Cell Lung Cancer Classification Using Densely Connected Neural Network." In 2024 International Conference on Computer Engineering, Network, and Intelligent Multimedia (CENIM). IEEE, 2024. https://doi.org/10.1109/cenim64038.2024.10882678.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Patel, Sagar S., Ramesh Natarajan, and Rebecca L. Heise. "Mechanotransduction of Primary Cilia in Lung Adenocarcinoma." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80435.

Pełny tekst źródła
Streszczenie:
Lung cancer causes more than 1 million deaths worldwide annually [1]. In a recent study by the American Cancer Society in 2011, more than 221,000 new cases of lung cancers were reported [2]. Out of these, the mortality rate was found in roughly 70% of the cases [2]. Lung cancer is divided into two major categories: small cell and non-small cell. In the United States, non-small cell lung cancer accounts for 85% of all lung cancers and is considered the most common type of lung cancer [2]. It is usually resistant to chemotherapy, therefore making it extremely difficult to treat [3]. Furthermore
Style APA, Harvard, Vancouver, ISO itp.
4

Gileva, M. S., E. G. Ufimceva, L. F. Gulyaeva, and V. V. Kozlov. "EX VIVO CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER CELLS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-308.

Pełny tekst źródła
Streszczenie:
The search for molecular markers for the identification of adenocarcinoma and squamous cell lung cancer remains an urgent problem. In this work, for the first time, an ex vivo method was used to isolate cells from tissue samples of patients with non-small cell lung cancer. Potential markers of this histological tumor type were analyzed, and the cellular composition of the immune microenvironment was also assessed, including depending on the smoking status of patients.
Style APA, Harvard, Vancouver, ISO itp.
5

Xing, Fuyong, and Lin Yang. "Robust cell segmentation for non-small cell lung cancer." In 2013 IEEE 10th International Symposium on Biomedical Imaging (ISBI 2013). IEEE, 2013. http://dx.doi.org/10.1109/isbi.2013.6556493.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Benammar, Sarra, Fatima Mraiche, Jensa Mariam Joseph, and Katerina Gorachinova. "Glucose and Transferrin Liganded PLGA Nanoparticles Internalization in Non-Small Lung Cancer Cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0227.

Pełny tekst źródła
Streszczenie:
Introduction: Recently, after a decade of confusing results, several studies pointed out that overexpression of GLUT1 (glucose transporter 1) is a biomarker of worse prognosis in NSCLC. Nonetheless, the presence of transferrin (Tf receptor), which is overexpressed in most cancer tissues and most lung cancers as well, in NSCLC is also an indicator of very poor prognosis. Therefore, these ligands can be used for active targeting of lung cancer cells and improved efficacy of internalization of cancer therapy using nanomedicines. Objectives: Having the background, the main goal of the project was
Style APA, Harvard, Vancouver, ISO itp.
7

Dias, Margarida, Raquel Marçoa, Rita Linhas, Sérgio Campainha, Sara Conde, and Ana Barroso. "Non-small cell lung cancer in never-smokers." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2796.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Neffati, O., L. Fekih, H. Kammoun, et al. "Prognostic factors in non-small cell lung cancer." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa4294.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Fu, Pin-Kuei. "Octogenarians With Operable Non-Small Cell Lung Cancer." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4407.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Hamedi, Z., S. Kamboj, S. Kumar, R. A. Jiwani, and N. Sharma. "Transformation of Non-Small Cell Lung Cancer (NSCLC) to Small Cell Lung Cancer (SCLC), Mechanism of Treatment Resistance?" In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4871.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Non-small cell lung cancer"

1

Freire, Mariana, Diana Martins, Maria Filomena Botelho, and Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.

Pełny tekst źródła
Streszczenie:
Review question / Objective: This systematic review aims to provide an overview of the immunotherapy resistance mechanisms and identify potential biomarkers associated with immunotherapy response in NSCLC, as well as examine new treatment options to overcome this hurdle. Condition being studied: Lung Cancer (LC) remains one of the leading cancers worldwide. In 2020, were globally estimated 2 206 771 new cases and 1 796 144 deaths, representing the uttermost frequent cause of cancer death. LC is classified histologically into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC),
Style APA, Harvard, Vancouver, ISO itp.
2

Watson, Mark A. Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada606182.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Kang, Jing, Jun Zhang, Zongsheng Tian, Ye Xu, Jiangbi Li, and Mingxina Li. The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0156.

Pełny tekst źródła
Streszczenie:
Review question / Objective: Population: histologically confirmed advanced NSCLC patients; Intervention: received immune-checkpoint inhibitor plus chemotherapy; Comparison:received chemotherapy; Outcome: reported OS, PFS, ORR and TRAEs; Study design: RCT. Condition being studied: Lung cancer is the primary cause of cancer-related deaths, with an estimated 2.20 million new cases and 1.79 million deaths every year, and 85% of all primary lung cancers are non-small cell lung cancer. Eligibility criteria: Studies were considered eligible if they met the following criteria: (1) being an randomized
Style APA, Harvard, Vancouver, ISO itp.
4

Nelkin, Barry D. Role of CDK5 as a Tumor Suppressor Gene in Non-Small Cell Lung Cancer. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada610950.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Li, Yong, Fang Yang, and Ya-Yong Huang. Sublobar resection versus ablation for stage I non-small-cell lung cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0075.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Chen, Zhong-Ke, and Yuan-Shun Xu. I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.10.0120.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Peng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.

Pełny tekst źródła
Streszczenie:
Review question / Objective: This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection of different regimens. Condition being studied: Immunotherapy is a relatively new treatment method for non-small cell lung cancer (NSCLC), and clinical studies confirmed that immune checkpoint inhibitors (ICIs) showed prominent efficacy in the treatment of NSCLC patients. This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection
Style APA, Harvard, Vancouver, ISO itp.
8

Peng, Ciyan, Jing Chen, Sini Li, and Jianhe Li. Comparative Efficacy of Chinese Herbal Injections Combined Western medicine for Non-small cell lung cancer: A Bayesian Network Meta-Analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.11.0068.

Pełny tekst źródła
Streszczenie:
Review question / Objective: Advanced lung cancer has become the top malignant tumor in terms of morbidity and mortality, and Chinese herbal injections combined with western drugs have been widely used to treat advanced non-small cell lung cancer. For this purpose, we conducted a Bayesian network analysis to systematically evaluate the efficacy of different herbal injections combined with western drugs in the treatment of NSCLC. Subjects: Patients diagnosed with NSCLC by pathological or cytological examination, locally advanced or those who refused surgical treatment were included, regardless
Style APA, Harvard, Vancouver, ISO itp.
9

Tong, Zhangwei, Fei Luo, Xiaojie Yang, and Jiangbo Lin. Platinum vs immunotherapy for early resectable non-small cell lung cancer: a systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.8.0064.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Shi, Yucong, Ziqi Chen, Sizhi Wu, et al. Comparison of Segmentectomy, Lobectomy and Wedge Resection for Early-stage Non-Small Cell Lung Cancer: A Bayesian analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.8.0090.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Non-small cell lung cancer” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii